Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 21, 2021 07:00 ET | Source: BeyondSpring, Inc.

BeyondSpring Announces First Patient Treated in Phase 2 Study with Plinabulin Combined with Nivolumab + Ipilimumab in Patients in 3rd Line Recurrent Small-Cell Lung Cancer Patients Who Failed Checkpoint Inhibitors

—The study is conducted by the Big Ten Cancer Research Consortium in up to 26 patients across 7 states in the U.S. —In the Phase 1 study, plinabulin combination was able to induce tumor responses...
October 20, 2021 07:00 ET | Source: BeyondSpring, Inc.

BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherpy at the AACR-NCI-EORTC Virtual International Conference to Further Support the Positive Clinical Data Already Reported for the Treatment of Small Cell Lung Cancer

Plinabulin’s anti-cancer effects were tested against approximately 80 patient-derived tumor models with small cell lung cancer (SCLC) tumor types being the most sensitive to plinabulin monotherapy at...
September 20, 2021 07:30 ET | Source: BeyondSpring, Inc.

BeyondSpring Pharmaceuticals Announces Positive Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patients with EGFR Wild Type at the European Society for Medical Oncology (ESMO) 2021 Congress

Study met the primary endpoint showing statistically significant improvement in overall survival (OS) for the combination (DP) vs. docetaxel (D).Study met key secondary endpoints showing statistically...
September 16, 2021 07:00 ET | Source: BeyondSpring, Inc.

BeyondSpring Pharmaceuticals Announces New Positive Data on Plinabulin from Its Chemotherapy-Induced Neutropenia Prevention Program at the European Society for Medical Oncology 2021 Congress

NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of innovative...
September 10, 2021 07:00 ET | Source: BeyondSpring, Inc.

BeyondSpring Announces Second Quarter 2021 Financial Results and Provides a Corporate Update

NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...
September 09, 2021 07:00 ET | Source: BeyondSpring, Inc.

BeyondSpring Announces Three Poster Presentations About its Chemotherapy-Induced Neutropenia Prevention Program at the European Society for Medical Oncology 2021 Congress

Plinabulin in combination with G-CSF is undergoing regulatory review for potential approval in the U.S. and China for the prevention of CIN, with a U.S. PDUFA date of November 30, 2021. NEW YORK,...
September 08, 2021 17:54 ET | Source: BeyondSpring, Inc.

BeyondSpring to Participate in the Upcoming September Conferences

NEW YORK, Sept. 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today...
September 07, 2021 08:00 ET | Source: BeyondSpring, Inc.

BeyondSpring to Host Second Quarter Financial Results and Corporate Update Conference Call on September 10, 2021

NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today...
August 31, 2021 07:00 ET | Source: BeyondSpring, Inc.

BeyondSpring Announces Late-Breaking Oral Presentation of Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination Versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patients with EGFR Wild Type at the European Society for Medical Oncology 2021 Congress

Topline results, released in early August, demonstrated improvement in overall survival (OS) for the combination vs. docetaxel alone as well as improvement in ORR, PFS, 24- and 36-month OS rates and...
August 26, 2021 07:00 ET | Source: BeyondSpring, Inc.

BeyondSpring Announces Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals for Plinabulin in Greater China

Wanchunbulin, BeyondSpring’s 58%-owned subsidiary in China, to partner with Hengrui, the leader in oncology product R&D and commercialization in China, for the exclusive commercial and...